September 20, 2017
The MPN Research Foundation (MPNRF), a patient-led organization representing over 300,000 MPN patients in the U.S. alone, is proud to announce the commencement of an innovative approach to finding a new use for a drug that has the potential to cure both blood and solid tumor cancers.
The MPNRF Interferon (IFN) Initiative is a multi-center project which will bring together internationally recognized experts in both blood and solid tumors to determine how cytokine-driven pathways affect the trajectory of the MPNs, a closely-related group of progressive blood cancers. The collaboration among this group of scientists is unprecedented and speaks to their drive to answer this question, which could have wide-ranging impact on the lives of people living with cancer. Specifically, the project is aimed at defining:
How and why targeting the IFN pathway reduces the burden of mutated stem cells in MPN patients.
- Why targeting this pathway is effective for some MPN patients but not others.
- Why the positive effects of targeting this pathway are not permanent.
This initiative will be funded by MPN patients and supporters, and by generous unrestricted contributions from PharmaEssentia and Incyte.
Interferon (IFN) is a drug that has proven to be effective in other diseases (e.g., hepatitis C), but has largely been replaced by a new generation drugs for those diseases. However, it remains the single treatment that provides disease-altering effects for MPN patients, and understanding its mechanism of action for MPNs can lead to better interferon compounds and potentially other drugs in the IFN pathway that can change the prognosis for MPN and other cancer patients.
Barbara Van Husen, President of MPNRF, says, “We have long felt that a study of Interferon would be a unique opportunity to open new avenues of treatment for MPN patients. We held an Interferon Brainstorming Session in 2016 at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, and became convinced we should spearhead this effort.”
“Working together and sharing knowledge is key,” says Leonidas Platanias, MD, PhD, Director of the Lurie Cancer Center, Jesse, Sara, Andrew, Abigail, Benjamin and Elizabeth Lurie Professor of Oncology and lead investigator of the multicenter effort. “As our understanding of complex cytokine pathways…